Information Provided By: 
Fly News Breaks for February 9, 2017
OSUR
Feb 9, 2017 | 07:48 EDT
Canaccord analyst Mark Massaro noted OraSure delivered solid Q4 results and gave good guidance for 2017. He said ongoing positive developments from its HCV business coupled with strong traction from its DNA Genotek business set it up for growth in 2017 and beyond. Massaro reiterated his Buy rating and raised his price target to $12 from $11 on OraSure shares. This note corrects an earlier version with an incorrect price target.
News For OSUR From the Last 2 Days
There are no results for your query OSUR
